`
`Efficacy and Safety of BG00012 in MS Full Text View ClinicalTrials.gov
`
`A service of the U.S. National Institutes of Health
`
`Efficacy and Safety of BG00012 in MS
`
`This study has been completed.
`
`Sponsor:
`Biogen
`
`Information provided by:
`Biogen
`
`ClinicalTrials.gov Identifier:
`NCT00168701
`
`First received: September 9, 2005
`Last updated: November 14, 2007
`Last verified: November 2007
`History of Changes
`
`Full Text View
`
`Tabular View
`
`No Study Results Posted
`
`Disclaimer
`
`How to Read a Study Record
`
` Purpose
`
`Determine the efficacy,safety, and tolerability of BG00012 in MS patients.
`
`Condition
`
`Multiple Sclerosis
`
`Intervention
`
`Drug: BG00012
`
`Phase
`
`Phase 2
`
`Interventional
`Study Type:
`Study Design: Allocation: Randomized
`Endpoint Classification: Safety/Efficacy Study
`Intervention Model: Parallel Assignment
`Masking: DoubleBlind
`Primary Purpose: Treatment
`
`Official Title:
`
`DoubleBlind, PlaceboControlled, DoseRanging Study to Determine the Efficacy and Safety of BG00012 in Subjects With
`RelapsingRemitting Multiple Sclerosis
`
`Resource links provided by NLM:
`
`Genetics Home Reference related topics: multiple sclerosis
`
`MedlinePlus related topics: Multiple Sclerosis
`
`Drug Information available for: Dimethyl fumarate
`
`U.S. FDA Resources
`
`Further study details as provided by Biogen:
`
`Primary Outcome Measures:
`The primary endpoint for the primary objective is the total number of MRI lesions at Weeks 12, 16, 20, and 24.
`
`Secondary Outcome Measures:
`The secondary endpoints will include measuring the changes in MRIs from baseline until Week 24, changes in other MS measurements q12
`weeks, and the annualized relapse rate and proportion of changes at Weeks 24 and 48.
`
`260
`Estimated Enrollment:
`October 2004
`Study Start Date:
`Study Completion Date: March 2006
`
`Detailed Description:
`The study will be divided into two parts: Part 1 will be a 24week, blinded, placebocontrolled treatment phase followed by Part 2, a 24week
`blinded, safety extension phase in which all subjects will receive BG00012.
`https://clinicaltrials.gov/show/NCT00168701
`
`1/3
`
`
`
`9/19/2015
` Eligibility
`
`Efficacy and Safety of BG00012 in MS Full Text View ClinicalTrials.gov
`
`18 Years to 55 Years
`Ages Eligible for Study:
`Both
`Genders Eligible for Study:
`Accepts Healthy Volunteers: No
`
`Criteria
`Inclusion Criteria:
`1. Must be 18 to 55 years old, inclusive, at the time of informed consent.
`2. Must have a confirmed diagnosis of relapsingremitting MS according to McDonald criteria #14 (McDonald et al, 2001; Appendix 2).
`3. Must have a baseline EDSS between 0.0 and 5.0, inclusive.
`5. Must have experienced at least one relapse within the 12 months prior to randomization, with a prior cranial MRI demonstrating lesion(s)
`consistent with MS OR show evidence of Gdenhancing lesions of the brain on an MRI performed within the 6 weeks.
`6. Male and female subjects must be willing to take appropriate measures to prevent pregnancy.
`Exclusion Criteria:
`1. Primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996 [Appendix 3]).
`2. History of malignancy.
`3. History of severe allergic or anaphylactic reactions or known drug hypersensitivity.
`4. History of abnormal laboratory results indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic,
`urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic (other than MS), and/or other major disease.
`5. History of human immunodeficiency virus (HIV).
`6. History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to randomization.
`7. An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse
`prior to randomization.
`8. Body weight >100 kg.
`9. Positive for hepatitis C antibody and/or positive for hepatitis B surface antigen (HBsAg) at screening.
`10. Any of the following abnormal blood tests at screening.
`11. Any previous treatment with FUMADERM®, FAG201, or BG00012.
`12. A medication history that precludes entry into the study.
`13. Female subjects who are currently pregnant or breastfeeding.
`
` Contacts and Locations
`
`Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a
`study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general
`information, see Learn About Clinical Studies.
`
`Please refer to this study by its ClinicalTrials.gov identifier: NCT00168701
`
` Show 42 Study Locations
`
`Sponsors and Collaborators
`Biogen
`
`Investigators
`Kantonsspital Basel
`Principal Investigator: Ludwig Kappos, Prof
`Study Director:
`Gilmore O'Neill, MB, MRCPI, MMedSc Biogen
`
` More Information
`
`No publications provided by Biogen
`
`Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
`
`Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, O'Gorman J, Novas M, Dawson KT, Phillips JT. BG12 (dimethyl fumarate):
`a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014 Feb;30(2):25162. doi: 10.1185/03007995.2013.849236. Epub
`2013 Oct 22. Review.
`
`Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E,
`Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with
`
`https://clinicaltrials.gov/show/NCT00168701
`
`2/3
`
`
`
`Efficacy and Safety of BG00012 in MS Full Text View ClinicalTrials.gov
`9/19/2015
`relapsingremitting multiple sclerosis: a multicentre, randomised, doubleblind, placebocontrolled phase IIb study. Lancet. 2008 Oct
`25;372(9648):146372. doi: 10.1016/S01406736(08)616190. Erratum in: Lancet. 2009 Apr 18;373(9672):1340.
`
`ClinicalTrials.gov Identifier: NCT00168701 History of Changes
`Other Study ID Numbers:
`C1900
`Study First Received:
`September 9, 2005
`Last Updated:
`November 14, 2007
`Health Authority:
`United Kingdom: Medicines and Healthcare Products Regulatory Agency
`Germany: Federal Institute for Drugs and Medical Devices
`Netherlands: Medicines Evaluation Board (MEB)
`Czech Republic: State Institute for Drug Control
`Poland: Ministry of Health
`Hungary: National Institute of Pharmacy
`Switzerland: Swissmedic
`Turkey: Ministry of Health
`Sweden: Medical Products Agency
`Russia: Pharmacological Committee, Ministry of Health
`
`Keywords provided by Biogen:
`Multiple Sclerosis
`MRI
`
`Additional relevant MeSH terms:
`Multiple Sclerosis
`Multiple Sclerosis, RelapsingRemitting
`Sclerosis
`Autoimmune Diseases
`Autoimmune Diseases of the Nervous System
`Demyelinating Autoimmune Diseases, CNS
`Demyelinating Diseases
`Immune System Diseases
`Nervous System Diseases
`
`ClinicalTrials.gov processed this record on September 18, 2015
`
`Pathologic Processes
`Dimethyl fumarate
`Dermatologic Agents
`Immunologic Factors
`Immunosuppressive Agents
`Pharmacologic Actions
`Physiological Effects of Drugs
`RadiationSensitizing Agents
`Therapeutic Uses
`
`https://clinicaltrials.gov/show/NCT00168701
`
`3/3